Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
K2 HealthVentures
AddedFeb 13, 2024
UpdatedJun 28, 2026
K2 HealthVentures

K2 HealthVentures

Operating

K2 HealthVentures: An alternative investment firm providing flexible, long-term financing to innovative healthcare companies.

Location
Boston, MA, US
Firm
Compare
Portfolio
Employees
Website

Investments

Vedanta Biosciences
Vedanta Biosciences

Total Raised

$433.1M

Rounds

15

Series E$106.5MApril 2023
Alto Neuroscience
Alto Neuroscience

Total Raised

$239.3M

Rounds

10

Debt Financing$35MJanuary 2023
Alignment Healthcare
Alignment Healthcare

Total Raised

$375M

Rounds

5

Post Ipo EquityJanuary 2023
DispatchHealth
DispatchHealth

Total Raised

$733.2M

Rounds

7

Debt FinancingNovember 2022
Inari Agriculture
Inari Agriculture

Total Raised

$609M

Rounds

7

Debt FinancingOctober 2022
Debt Financing$45MApril 2020
TScan Therapeutics
TScan Therapeutics
Public

Total Raised

$197.5M

Rounds

6

Debt Financing$60MSeptember 2022
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Debt Financing$50MApril 2022
OncXerna Therapeutics
OncXerna Therapeutics

Total Raised

$126.5M

Rounds

3

Series Unknown$30MMarch 2022
Platelet BioGenesis
Platelet BioGenesis

Total Raised

$132.1M

Rounds

14

Series B$75.5MNovember 2021
Click Therapeutics
Click Therapeutics
Public

Total Raised

$946.4M

Rounds

12

Series B$52MOctober 2021
Debt Financing$30MDecember 2020
Invaio Sciences
Invaio Sciences

Total Raised

$138.9M

Rounds

4

Debt Financing$50MOctober 2021
Aptinyx
Aptinyx
Public

Total Raised

$273.9M

Rounds

7

Post Ipo Debt$50MSeptember 2021
Vesta Healthcare
Vesta Healthcare

Total Raised

$105M

Rounds

3

Series Unknown$65MApril 2021
Molecular Templates
Molecular Templates
Public

Total Raised

$348.2M

Rounds

16

Post Ipo Debt$45MMarch 2020